ロード中...
A Phase II Study of the Gamma Secretase Inhibitor RO4929097 in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma
PURPOSE: The notch pathway is overexpressed in pancreatic adenocarcinoma. RO4929097, an oral inhibitor of the γ-secretase enzyme has been safely given as a single agent in patients with advanced solid tumors. We aimed to evaluate the efficacy of RO4929097 in patients with pancreatic adenocarcinoma (...
保存先:
| 出版年: | Invest New Drugs |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4292847/ https://ncbi.nlm.nih.gov/pubmed/24668033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0083-8 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|